• Journal Article

Clinical and biological moderators of response to naltrexone in alcohol dependence: A systematic review of the evidence


Garbutt, J. C., Greenblatt, A., West, S., Morgan, L., Kampov-Polevoy, A., Jordan, H., & Bobashev, G. (2014). Clinical and biological moderators of response to naltrexone in alcohol dependence: A systematic review of the evidence. Addiction, 109(8), 1274-1284. DOI: 10.1111/add.12557


The goal of this systematic review was to identify moderators of naltrexone efficacy in the treatment of alcohol dependence.

We searched Pubmed, CINHAL, Embase, Psycinfo and the Cochrane Library from 1990 to April 2012 and reference lists of pertinent review articles, which yielded 622 trial, pooled analysis, and review articles. Using pre-established eligibility criteria, two reviewers independently determined whether abstracts contained evidence of demographic or biological characteristics, i.e. moderators, influencing naltrexone response in alcohol dependence. We assessed each publication for risk of bias and evaluated the strength of the body of evidence for each moderator.

Twenty-eight publications (on 20 studies) met criteria for data synthesis. These included 26 publications from 12 randomized, placebo-controlled trials, 3 non-randomized, non-placebo studies, and 1 randomized, non-placebo study. In addition, there were 2 publications from pooled analyses of 4 randomized, placebo-controlled trials. Family history of alcohol problems and the Asn40Asp polymorphism of the ?-opioid receptor gene showed a positive association with efficacy in four out of five and three out of five studies respectively. Other moderators reported to be associated with efficacy included male sex (2/5 studies), pretreatment drinking (2/2 studies), and high craving (2/5 studies). However, the overall risk of bias in the published literature is high.

The identification of naltrexone-responsive alcohol dependent patients is still in development. Studies to date point to two potential moderators—family history and presence of the OPRM1 Asn40Asp polymorphism—as having the strongest evidence. However, the data to date are still insufficient to recommend that any moderator be used in determining clinical treatment.